Collegium to Acquire US Rights of Assertio’s Nucynta Franchise for $375M

 Collegium to Acquire US Rights of Assertio’s Nucynta Franchise for $375M

Collegium to Acquire US Rights of Assertio’s Nucynta Franchise for $375M

Shots:

  • Assertio to receive $375M upfront in cash and fewer royalties in 2020, subject to certain adjustments. Collegium to get the US license or the Nucynta Franchise and will not pay royalties to Assertio with the anticipated completion of the transaction on Feb 14, 2020
  • Additionally, Collegium will continue to pay 14% royalties on net sales on Nucynta Franchise to Grunenthal and will not pay royalties on sales >$180M
  • In 2017, Collegium signed a commercialization agreement with Depomed (now Assertio) for the Nucynta franchise in exchange for royalties with an annual commitment of $135M for the first 4yrs and after 4yrs. the royalty mechanism remains the same but without a minimum

Click here ­to­ read full press release/ article | Ref: Business wire | Image: Collegium

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post